Thus, while its expression synergisms with the ATP2B3 (ATPase, Ca++ transporting, plasma membrane 3) and KLK2 (kallikrein-related peptidase 2) in NOR are not modified by ccRCC, the antagonistic expression with the AP2A1 is switched to a synergistic one in all three cancer nodules. The gene discussed is KLK2; the disease is nonpapillary renal cell carcinoma.